Ibotta's valuation reset challenges the deep-value thesis as EBITDA lags revenue recovery.

What happened

Ibotta's share price surged 83% year-to-date, driving its valuation to a premium versus digital advertising peers, according to a recent Seeking Alpha analysis. The company returned to year-over-year revenue growth in 2Q26 for the first time since 1Q25, helped by expanded publisher and redeemer networks including a new 7-Eleven partnership. However, EBITDA is falling due to elevated investment costs, and revenue growth remains tied to unpredictable FMCG advertiser budgets. The DeepValue master report had previously flagged Ibotta as a potential buy at distressed valuations in late 2025, when it traded near $24 with single-digit P/E multiples. That valuation cushion has now largely evaporated, leaving a less compelling risk/reward profile despite improving top-line momentum.

Implication

The original deep-value thesis was predicated on a depressed multiple that has now normalized, reducing the margin of safety for new buyers. While the return to revenue growth is encouraging, the concurrent decline in EBITDA indicates that the growth is being bought with heavier investment, which may compress margins if revenue proves cyclical. Management's own caution about the sustainability of growth and profitability, as noted in filings, remains highly relevant. The new 7-Eleven partnership and publisher expansion do strengthen the network but also raise fixed costs, meaning EBITDA could stay under pressure near term. Investors should await clearer evidence of EBITDA stabilization and durable revenue growth before adding; a pullback to more reasonable multiples would restore a more attractive entry point.

Thesis delta

The original thesis saw Ibotta as a deep value opportunity trading at distressed multiples with optionality on revenue stabilization. The 83% YTD surge has eliminated that discount, and the stock now trades at a premium to ad tech peers, sharply reducing the margin of safety. Although revenue growth has returned, EBITDA is declining due to growth investments, so the profitability inflection that would justify the premium has not yet occurred, shifting the balance from asymmetric upside to a more balanced risk/reward.